

In the claims:

1. (Presently amended) A method for inhibiting the proliferation of tumor cells comprising endogenous B-cell maturation antigen (BCMA) or transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI), comprising administering to the tumor cells a composition that comprises an antibody component, wherein the antibody component binds both ~~the B-cell maturation antigen (BCMA) and the transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI)~~ at an epitope within a polypeptide consisting of amino acid residues 105 to 166 of SEQ ID NO: 4.

2. (Original) The method of claim 1, wherein the composition is administered to cells cultured *in vitro*.

3. (Original) The method of claim 1, wherein the composition is a pharmaceutical composition, and wherein the pharmaceutical composition is administered to a subject, which has a tumor.

4. (Original) The method of claim 1, wherein the composition comprises an anti-BCMA-TACI antibody component that is a naked BCMA-TACI antibody.

5. (Original) The method of claim 1, wherein the composition comprises an anti-BCMA-TACI antibody component that is a naked BCMA-TACI antibody fragment.

6. (Original) The method of claim 1, wherein the composition comprises an immunoconjugate that comprises an anti-BCMA-TACI antibody component and a therapeutic agent.

7. (Original) The method of claim 6, wherein the therapeutic agent is selected from the group consisting of chemotherapeutic drug, cytotoxin, immunomodulator, chelator, boron compound, photoactive agent, photoactive dye, and radioisotope.

8. (Original) The method of claim 1, wherein the composition comprises an antibody fusion protein that comprises an anti-BCMA-TACI antibody component and a cytotoxic polypeptide.

9. (Cancelled)

10. (Original) The method of claim 1 9, wherein the antibody component binds to a polypeptide consisting of amino acid residues 110 to 118 of SEQ ID NO:4.

Claims 11-24 (Cancelled).